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Rotavirus C (RVC) causes sporadic gastroenteritis in adults and is an established enteric pathogen of
swine. Because RVC strains grow poorly in cell culture, which hinders generation of virion-derived RVC
triple-layered-particle (TLP) structures, we used the known Rotavirus A (RVA) capsid structure to model
the human RVC (Bristol) capsid. Comparative analysis of RVA and RVC capsid proteins showed major
differences at the VP7 layer, an important target region for vaccine development due to its antigenic
properties. Our model predicted the presence of a surface extended loop in RVC, which could form a
major antigenic site on the capsid. We analyzed variations in the glycosylation patterns among RV
capsids and identiﬁed group speciﬁc conserved sites. In addition, our results showed a smaller RVC VP4
foot, which protrudes toward the intermediate VP6 layer, in comparison to that of RVA. Finally, our
results showed major structural differences at the VP8* glycan recognition sites.
Published by Elsevier Inc.Introduction
Rotaviruses, members of the Reoviridae, are a common cause of
severe gastroenteritis in humans and animals (Estes and Kapikian,
2007). The rotavirus genome consists of 11 segments of double-
stranded RNA (dsRNA) that encode six structural proteins (VP1-
VP4, VP6 and VP7) and ﬁve or six non-structural proteins (NSP1-
NSP6) depending on the virus strain (Estes and Kapikian, 2007;
Ciarlet and Estes, 2002). Rotaviruses have been resolved into
8 species (RVA to RVH) based on phylogenetic analysis
(Matthijnssens et al., 2012). RVA, RVB, RVC and RVH have been
recovered from humans and animal species, while RVD, RVF and
RVG have been isolated only from birds and RVE from swine
(Patton, 2012; Wakuda et al., 2011). The RVA group is the most
widely studied as its members are the leading cause of life-
threatening diarrhea in infants and young children globally. In
contrast to the endemic incidence of RVA disease, RVC infections
are associated with sporadic and limited outbreaks of gastro-
enteritis in children and adults. Such infections have been noted
both in developed and developing countries (Kuzuya et al., 1998;eases, NIAID, NIH, 50 South
, 23186.
ine, University of Maryland,Nilsson et al., 2000; Rahman et al., 2005; Von Bonsdorf and
Svensson, 1988). Many RVC infections may be asymptomatic or
subclinical in nature, based on seroprevalence studies indicating
that up to 50% of adults have anti-RVC antibodies in some geo-
graphic regions. RVC are also known to infect swine, cattle, dogs
and ferrets and are a particularly important cause of gastro-
enteritis in pigs during the ﬁrst 8 weeks of life. The widespread
nature of swine RVC infections is suggested by seroprevalence
studies revealing that 70–100% of adult pigs have anti-RVC
antibodies.
High-resolution structures are available for the RVA capsid and
most of its protein components. Based on these data, the RV virion
has been determined to be a non-enveloped 100-nm icosahedral
particle consisting of three concentric layers of protein (triple-
layered particle (TLP) (Estes and Kapikian, 2007; Chen et al., 2009;
Estrozi et al., 2013; McClain et al., 2010; Settembre et al., 2011).
The innermost layer-the core shell-is a T¼1 icosahedron com-
posed of 60 asymmetric dimers of VP2 (VP2A and VP2B) that
encloses the genome and two minor proteins: the RNA-dependent
RNA polymerase VP1 and the RNA capping enzyme VP3. The
intermediate layer has T¼13 symmetry and is formed by 260 tri-
mers of VP6. The outermost layer is composed of 260 trimers of
the glycoprotein VP7, also arranged with T¼13 symmetry, and 60
spikes formed by asymmetric VP4 trimers. Exposure to trypsin-
like proteases cleaves RVA VP4 into two polypeptides, VP8* and
VP5* and enhances virus infectivity (Dormitzer et al., 2004). The
VP7 and VP4 proteins contain multiple antigenic epitopes that can
E. Eren et al. / Virology 487 (2016) 150–162 151induce the production of neutralizing antibodies and, thus, are key
targets for vaccine development.
A classiﬁcation system has been adopted that allows assign-
ment of G (glycoprotein) and P (protease-sensitive) genotypes to
the VP7 and VP4 genes of RVA strains, respectively (Estes and
Kapikian, 2007). To date, a total of 27G and 37P genotypes have
been identiﬁed for the RVA. In contrast to RVA, much less genetic
diversity has been found for the RVC; however, this may in part
reﬂect the relatively fewer G and P-typing and surveillance studies
that have been performed for the RVC. Although a VP7- and VP4-
genotype classiﬁcation system has yet to be formally established
for the RVC, 9G-genotypes (G1–G9) and 6P-genotypes (P[1]–P[3])
have been proposed based on phylogenetic analysis of human and
animal RVC sequences (Collins et al., 2008; Jiang et al., 1999;
Martella et al., 2007; Marthaler et al., 2013; Suzuki et al., 2015).
The porcine RVC are the most diverse and include viruses with G1,
G3, G5–G9P[1] genotypes. Typically, human RVCs have a G4P[2]
genotype and bovine RVCs have a G2P[3] genotype (Collins et al.,
2008; Martella et al., 2007; Marthaler et al., 2013; Jiang et al.,
1995). There are reports suggesting interspecies transmission of
RVC strains, but little information is available concerning the fre-
quency of such events or its impact on RVC evolution or diversity.
Dual infections by RVA and RVC in humans and animals have been
reported (Jiang et al., 1995). However, reassortment of RVA and
RVC strains to form RVA/RVC hybrid viruses has not been
described.
There is no structural information available for the RVC virion,
including its outer capsid VP7 and VP4 components. The lack of
such information hampers the ability to deﬁne antigenic regions of
the RVC capsid that could be useful for vaccine development and
monitoring virus diversity and evolution. Moreover, comparison of
a RVC capsid structure with that of RVA would allow better
understanding of virus features that are shared, or unique, among
RV groups. RVC grows poorly in cell cultures, which makes it dif-
ﬁcult to obtain the necessary quantities of virus particles required
for generating structure information by cryoelectron microscopy
(Cryo-EM) or X-ray crystallography. Importantly, previous studies
have shown that co-expression of the RVA intermediate capsid
protein VP6 (A-VP6) with the RVC core protein VP2 (C-VP2) using
recombinant baculoviruses generates C-VP2/A-VP6 double-layered
particles (DLPs) (Kim et al., 2002; Tosser et al., 1992). Similarly,
recombinant baculoviruses were also successfully used to produce
RVA/RVC hybrid TLPs, including those composed of A-VP2/C-VP6/
C-VP7, A-VP2/C-VP6/A-VP7 and A-VP2/A-VP6/C-VP7 (Kim et al.,
2002). The ability to produce RVA/RVC hybrid particles indicates a
high degree of structural conservation between RVC and RVA
capsid proteins, and the presence of protein–protein interfaces
that function similarly. Supported by these observations, we used
a homology modeling based approach to generate a RVC capsid
structure model, one found to score with a high conﬁdence value.
Notably, the model suggests that the surface topology of RVC
capsid is different from that of the RVA capsid, principally due to
an additional extended surface loop on the C-VP7 trimer that is
likely to represent a dominant antigenic epitope. The C-VP4
attachment protein is also unique, containing a smaller VP6-
interacting foot.Methods
Homology modeling and capsid generation
Human RVC (Bristol strain) VP2 (GenBank YP_392489), VP4
(YP_392514), and VP7 (YP_392513) were threaded against simian
RVA (RRV strain) VP2, VP4, and VP7 (PDB IDs 3N09 and 3IYU) and
modeled using the Phyre2 protein-fold recognition server (Kelleyand Sternberg, 2009). Similarly, human RVC (Bristol strain) VP6
(YP_392512) was threaded against bovine RVA (RF strain) VP6
(PDB ID 1QHD) and modeled by Phyre2. The models were eval-
uated using the protein structure validation software suite (PSVS)
(http://psvs-1_5-dev.nesg.org/) (Bhattacharya et al., 2007). Model
and template structure comparisons and Cα backbone root-mean-
square deviation (RMSD) value calculations were carried out using
PDBeFold (http://www.ebi.ac.uk/msd-srv/ssm) (Krissinel and
Henrick, 2004). The RVC 31-mer asymmetric unit was generated
by structural alignment of RVC models with RVA asymmetric unit
proteins (PDB IDs 3N09 and 3IYU) using Chimera (Pettersen et al.,
2004) and by combination of aligned RVC structures to form the
entire 31-mer asymmetric unit using PyMol (The PyMol Molecular
Graphics System, Version 1.5.0.4., Schrodinger LLC). Minimization
of the asymmetric unit was carried out using Chimera, applying
100 steepest descent steps and 3 conjugate gradient steps.
Asymmetric unit protein geometries were evaluated using Mol-
Probity (http://molprobity.biochem.duke.edu/) (Chen et al., 2010).
A full capsid structure was modeled using Chimera after applica-
tion of icosahedral capsid BIOMT values obtained from VIPERdb
(http://viperdb.scripps.edu/) to the RVC asymmetric unit (Shep-
herd et al., 2006). Porcine G6 VP7 (ABR28507) was modeled using
Phyre2, using RVA VP7 (PDB ID 3IYU) as a template. Model eva-
luation was carried out using PSVS and PDBeFold.
Sequence alignment and phylogenetic tree building
RVC VP4 and VP7 gene sequences were obtained by running
BLAST analyses against human RVC (Bristol strain) VP4 and VP7
with the accession numbers NC_007572 and NC_007571, respec-
tively. Best models for phylogenetic trees were analyzed by MEGA
(version 6.06) (Tamura et al., 2013). For both VP4 and VP7, Max-
imum Likelihood (ML) trees were constructed using general time
reversible (GTR) model and Gþ I (gamma distributed with invar-
iant sites). RVC VP4 and VP7 protein sequences were obtained by
running BLAST analyses against human RVC (Bristol strain) VP4
and VP7 with the accession numbers YP_392514 and YP_392513,
respectively. Phylogenetic analyses and tree constructions of RVC
VP4 and VP7 proteins were done by MEGA using the Neighbor-
Joining method. Bootstrap analyses were carried out by MEGA
using a value of 1000. Phylogenetic trees were edited using FigTree
(v1.4.1). RVA (RRV strain) VP4 (ACC94315) and VP7 (ACC94320)
sequences were obtained from the GenBank (Benson et al., 2005).
Sequence alignments of RVA and RVC proteins were carried out
using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/)
(Sievers et al., 2011). RVA VP7 protein sequences were obtained by
running a BLAST analysis against simian RVA (RRV strain) VP7
(ACC94320). RVA VP7 phylogenetic tree was constructed by MEGA
using the Neighbor-Joining method. Sequence logo for the RVC
VP7 insertion was created by WebLogo (http://weblogo.berkeley.
edu/) (Crooks et al., 2004).
Prediction of antigenic epitopes and glycosylation and trypsin-
cleavage sites
Antigenic epitopes were predicted using EPCES (http://sysbio.
unl.edu/EPCES/) (Liang et al., 2007) and structures were colored
according to the antigenicity prediction scoring using PyMol, by
application of B factor values generated by the program. N-linked
glycosylation sites of RVC and RVA VP7 proteins were predicted
using N-GlycoSite (http://www.hiv.lanl.gov/content/sequence/GLY
COSITE/glycosite.html) (Shaw and Zhang, 2013). Analysis of
N-linked glycosylation site accessibility in VP7 structures was
carried out using GlyProt (http://www.glycosciences.de/modeling/
glyprot/php/main.php) (Bohne-Lang and von der Lieth, 2005).
Table 1
Homology model evaluation statistics.
Model % Identity RMSDa Q-score Ramachandran (%) Verify3D
Human VP2 47.3 0.00 1.00 93.9b/3.8c/2.3d 0.36
Human VP4 31.9 0.54 0.84 94.4/3.3/2.3 0.27
Human VP6 43.0 0.16 0.98 99.4/0.3/0.3 0.40
Human VP7 35.5 0.11 0.96 95.9/2.9/1.3 0.37
Porcine-G6 VP7 36.0 0.11 0.94 99.5/3.3/1.7 0.37
a Values were calculated for Cα backbone.
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web.expasy.org/peptide_cutter/) (Gasteiger et al., 2005).
VP8* structural alignments and ligand docking
Alignment of human RVC (Bristol) VP8* model with simian RVA
(RRV) (PDB ID 1KQR) was carried out using DaliLite (http://www.
ebi.ac.uk/Tools/structure/dalilite/) (Hasegawa and Holm, 2009).
Electrostatic surface potentials were calculated using PyMol APBS
(Adaptive Poisson–Boltzmann Solver) tool.b Allowed regions.
c Generously allowed regions.
d Disallowed regions.Results
Homology model of the human RVC capsid
High-resolution structural information has been obtained for
the RVA TLP and its protein components through X-ray crystal-
lography, NMR and single particle cryo-EM (Chen et al., 2009;
Estrozi et al., 2013; McClain et al., 2010; Settembre et al., 2011;
Aoki et al., 2009; Hu et al., 2012; Mathieu et al., 2001). To produce
a model of the RVC capsid VP2, VP4, VP6 and VP7 proteins of the
human RVC (Bristol strain) were individually modeled using three
different homology-modeling programs, Phyre2, I-TASSER and
MODELLER, either by threading against a database of structures or
user-speciﬁed RVA capsid protein structures. Phyre2 uses the
alignment of hidden Markov models via HHsearch to signiﬁcantly
improve accuracy of alignment and detection rate (Kelley and
Sternberg, 2009). I-TASSER builds models based on multiple
threading alignments by LOMETS (Local Meta-Threading Server)
and iterative TASSER (Threading/Assembly/Reﬁnement) simula-
tions (Zhang, 2008). MODELLER implements a technique known as
satisfaction of spatial restraints that uses a set of geometrical cri-
teria to create a probability density function for the location of
each atom in the protein (Fiser and Sali, 2003). In addition,
MODELLER incorporates ab initio structure of protein loops, which
are often highly variable and therefore difﬁcult to predict by
homology modeling. The resultant models generated by the dif-
ferent homology modeling programs were evaluated using PSVS
(protein structure validation software suite) that integrates ana-
lyses from several structure evaluation tools including PROCHECK,
MolProbity, Verify3D and ProsaII, and PDBeFold that performs the
multiple comparison and 3D alignment of protein structures. In
general, I-TASSER and MODELLER generated models had slightly
better Ramachandran-based restraints (1–3%) and lower bond
angle (0.1–1.6 Å) and bond length deviations (0.01–0.05 Å) (data
not shown). On the other hand, Phyre2 models yielded lower
molprobity clashscores (6–30%) and higher overall model qualities
(0–40%) (data not shown). In addition, when compared to the
template structures Phyre2 models yielded lowest root mean
square deviation (RMSD) values and highest Q-scores (quality of
alignment), which represent the quality function of Cα alignment,
maximized by the SSM (secondary structure matching) algorithm
(data not shown). Based on these assessments, Phyre2 models of
RVC VP2, VP4 and VP7 threaded against the corresponding capsid
proteins of the RVA RRV strain (PDB IDs 3N09 and 3IYU) and RVC
VP6 threaded against the RVA RF strain (PDB ID 1QHD) were
chosen to generate the RVC capsid model (Settembre et al., 2011;
Mathieu et al., 2001).
Alignment of RVC capsid protein models with RVA capsid proteins
revealed a high sequence similarity between RVC/RVA VP2 and VP6
proteins (443% identity), while RVC/RVA VP7 and VP4 were more
divergent (32–35% [Table 1]). All RVC models yielded favorable
Ramachandran-based restraints (493% in allowed regions) and
comparison of model structures with the template structures resu-
ted in low RMSD values (o0.6) for the Cα backbone (Table 1).Accordingly, Q-scores were 40.8 (1 is the highest score) indicating a
good structural alignment between the models and the templates. All
models yielded above average overall quality as assessed by Verify3D
which scores the compatibility of the 3D structure model with its
amino acid sequence (Table 1) (Eisenberg et al., 1997). In order to
generate a RVC 31-mer asymmetric unit, individual RVC models were
aligned with corresponding RVA asymmetric unit proteins using
Chimera (Fig. 1A). Protein geometries of both the RVC (model) and
RVA (template) asymmetric units were evaluated using MolProbity.
RVC model yielded a comparable MolProbity score in comparison to
RVA template (3.93 vs. 4.45). MolProbity score combines the clash-
score, rotamer and Ramachandran evaluations into a single score and
a lower score is an indication of “better” geometry. Full RVC capsid
model was produced from the asymmetric unit using Chimera after
application of BIOMT values for icosahedral capsids (Fig. 1B). RVC
capsid model was deposited to VIPERdb with the accession numbers
HRTVC1 (VP2-VP6 layer) and HRTVC2 (VP7-VP4 layer) (http://viperdb.
scripps.edu/info_page.php?VDB¼hrtvc1 and http://viperdb.scripps.
edu/info_page.php?VDB¼hrtvc2).
Full RVC capsid model was composed of 60 asymmetric VP2
dimers (A and B forms) arranged in T¼1 symmetry, 260 VP6 and
VP7 homotrimers arranged in T¼13 symmetry and 60 VP4 het-
erotrimers. The VP2 layer lacked the N-terminus aa 1–103 for
VP2A and 1-85 for VP2B. The N-terminus of VP2B forms ﬂexible
tethers (aa 1–92) that are thought to interact with VP1 and VP3,
and play an important role in their encapsidation (Estrozi et al.,
2013; Zeng et al., 1998). In the RVC capsid model VP4 was modeled
to mimic the unusual symmetry of the RVAVP4 spike. Accordingly,
the base of the spike formed a trimer while the VP5* β-barrel
domains and the VP8* heads of only two VP4 molecules formed a
dimer. VP5* β-barrel domain of the third VP4 molecule formed a
diagonal “stalk” and the third VP8* head was missing from the
structure model.
Comparison of the RVA capsid and RVC capsid model showed
that both strains formed similarly sized and shaped DLPs and TLPs.
However, RVC capsid model contained “peak” regions at the VP7
layer that are not observed in RVA capsid structure (Fig. 1C).
Therefore, we analyzed RVC VP7 proteins and compared them to
RVA VP7 proteins.
RVC capsid glycoprotein VP7
In a previous study, 70 RVC VP7 proteins were resolved into a
number of distinct genotypes that displayed differences in host
speciﬁcities (Marthaler et al., 2013). Since the number of available
RVC VP7 sequences increased considerably, we reanalyzed the
phylogenetic variability of 168 RVC VP7 sequences from human,
porcine and bovine species, using the same 85% nucleotide cut-off
value (Fig. 2A). Our results were in agreement with the previous
study that deﬁned 9 distinct G-types, 7 of which were formed
by porcine strains. In order to compare the phenotypic variation
between RVC VP7s from different host groups we analyzed RVC
E. Eren et al. / Virology 487 (2016) 150–162 153VP7 protein sequences (N¼168). Phylogenetic analysis of amino
acid sequences revealed that both human and bovine RVC VP7
proteins were highly conserved (495% sequence identity) with
each clustering into single groups (Fig. 2B and Table 2). On the
other hand, porcine RVC VP7 proteins were divergent (69–99.7%
sequence identity), forming 4 major distinct groups (G3, G5/G9,
G1/G7 and G6/G8) with an 87% amino acid cut-off (Fig. 2B and
Table 2). Among these porcine-G3 VP7 shared the lowest inter-
group similarity with the other porcine groups (68.7–75.3%)
(Table 2).VP4
VP7
VP6
VP2
VP8*
VP5*
RVA VP7 RVC VP7
393 382 320 
Radius (Å)
H
Fig. 1. Human RVC capsid model. (A) RVC 31-mer asymmetric unit model consisting of 3
(VP8*) and body/stalk/foot (VP5*) illustrate products of trypsin cleavage. (B) Intact RVC
section of the capsid model (right). (C) RVA and RVC model VP7 layers colored accord
between the two VP7 layers, radii below 382 Å are shown in gray.
Fig. 2. Phylogenetic analysis of RVC VP7. (A) Phylogenetic tree constructed using 168 RV
protein sequences. Corresponding G-types (Marthaler et al., 2013) are shown in parenthSequence alignment of RVC VP7s with RVA VP7 showed the
presence a 9 amino acid (aa) long insertion (L9) located between
the RVC VP7 amino acids (aa) 83 and 93 (Fig. 3A). L9 is mostly
composed of non-polar amino acids and is present in all RVC VP7s
with some variations in the amino acid composition (Fig. 3B). The
most common sequences are A[VA][VI]GS[QP]GPG which are
found in over 80% of RVC VP7 proteins (Fig. 3B). Interestingly, most
porcine-G6 RVC VP7s (494%) were longer than the other RVC
VP7s (736 aa vs. 732 aa) and had an extra 4 aa serine-rich SS[ST]
[VLM] insertion (L4a) at the aa 244–245 (numbering is relative toVP4
VP7
VP6
VP2
 Model
RVC specific peak regions on 
a VP7 trimer surface
uman RVC Capsid Model
VP4 (blue), 13 VP7 (green), 13 VP6 (yellow) and 2 VP2 (orange) proteins. VP4 head
icosahedral capsid model formed from the asymmetrical unit (left) and a cross-
ing to radius from the center using Chimera. In order to emphasize the difference
C VP7 nucleotide sequences. (B) Phylogenetic tree constructed using 168 RVC VP7
esis. Bootstrap values corresponding to the main nodes in both trees are shown.
Table 2
Percent identity matrix of RVC VP7 proteinsa,b.
G1 G2 G3 G4 G5 G6 G7 G8 G9
G1 91–100
G2 74–75 98–100
G3 69–73 74–75 90–100
G4 85–87 73–74 71–72 96–100
G5 83–85 72–74 69–72 84–85 88–100
G6 78–79 78 71–72 80 77–79 92–100
G7 88–90 74 71–73 83–87 82–85 80–81 91–100
G8 77–78 76–78 70–71 79 75–79 87–89 79–80 100
G9 84–88 75–76 69–73 85–86 86–89 79–80 84–87 80 92–100
a Percent identity matrix of RVC VP7 proteins forming different G-types were calculated using a Kimura-corrected pairwise alignment with a gap opening penalty of
6 bits and a gap extension penalty of 1 bit.
b Number of independent sequences used for each G-type is as follows: G1: 20; G2: 8; G3: 9; G4: 52; G5: 10; G6: 53; G7: 10; G8: 1 and G9: 5.
Fig. 3. Sequence comparisons of RVC VP7 proteins with RVA VP7. (A) Representative alignment of RVC VP7 proteins with simian RVA. Accession numbers for sequences are:
ACC94320 for simian (RRV) RVA; YP_392513 (Bristol [G4]) for human RVC; AFR44611 (G1), AAC55009 (G3), BAQ15438 (G5), ABR28507 (G6), AJL35106 (G7), ACF33463 (G8)
and BAQ15448 (G9) for porcine RVC; and Q65527 (Shintoku [G2]) for bovine RVC. RVA antigenic sites 7-1a (red), 71-b (yellow) and 7-2 (green), L9 insertion (blue) and L4a
insertion (magenta) are indicated. (B) Sequence logo of RVC VP7 (aa 83–92) created using 166 sequences.
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E. Eren et al. / Virology 487 (2016) 150–162 155human RVC) position (Fig. 3A). L4a immediately precedes a 4 aa
variable surface loop (NX1X2 3 [L4b]) (aa 245–248) found in both
RVA and RVC VP7s (Fig. 3A). In order to determine the positions of
these insertions in the VP7 structure we analyzed human and
porcine-G6 RVC VP7 models and compared them to the RVA VP7
structure. In both the human and porcine-G6 VP7 models L9 forms
a surface exposed loop (Fig. 4A) that matches the VP7 surface
peaks in the RVC capsid model. In porcine-G6 VP7 model, L4a and
L4b together form an elongated surface exposed loop (L4) (Fig. 4A,
bottom).
Impact of RVC VP7 model L9 and L4a loops on surface topology
The positions of antigenic regions on VP7 trimer surfaces for
RVA have been determined by identiﬁcation of neutralization
escape mutants using various monoclonal antibodies (mABs) (Aoki
et al., 2009). RVA antigenic regions cluster roughly into two
regions designated 7-1 and 7-2 (Fig. 4B, left). Region 7-1 spans the
intersubunit boundary, and further divided into two subregions:
7-1a, on one side of the interface, and 7-1b on the other (Fig. 4B,
left). Among these 7-1 is the “immunodominant” region that is
recognized by 58 out of 68 tested antibodies (Aoki et al., 2009). We
mapped the RVA antigenic regions on human and porcine-G6 RVC
VP7 models to compare the topology of antigenic regions on VP7
surfaces and analyzed the effects of L9 and L4a insertions on these
regions. Since RVC/RVA VP7 backbones were highly similar (RMSD
0.11 and Q-score 0.96) most RVA antigenic regions were located in
roughly the same positions on RVC VP7 model surfaces (Fig. 4B).
However, L9 insertion resulted in an altered RVC VP7 model sur-
face topology at the 7-1a region (Fig. 4B, middle and right). On the
other hand, in the porcine-G6 VP7 model L4a was inserted into the
7-2 region (Fig. 4B, right).
In order to determine the antigenic properties of L9 and L4, we
analyzed both human and porcine-G6 VP7 model structures using
EPCES (Epitope Prediction by Consensus Scoring). EPCES uses six
different scoring functions including residue epitope propensity,
conservation score, side-chain energy score, contact number, sur-
face planarity score and secondary structure composition. Not7-1a 7
Simian RVA  
L9
Simian RVA
Porcine 4 RVC Model
Human RVC Model
Simian RVA
L9
L4a
L4b
N
N
C
C
L4b
Fig. 4. Comparison of RVA VP7 and RVC VP7 model structures. (A) Alignment of human R
RVA (PDB ID 3IYU_A) (gray) VP7 structure. L9 and L4a insertions are colored in blue an
representations of RVA and RVC VP7 model trimers. Antigenic regions selected by various
human (middle) and porcine-G6 RVC (right) models. Locations of L9, L4a, and L4b are asurprisingly, both loops received high antigenicity scores (490%)
that matched with their surface location (Fig. 5).
RVC VP7 N-linked glycosylation sites
It has been shown that N-linked glycosylation of RV VP7 is
required for correct disulﬁde bond formation and folding of the
protein in the endoplasmic reticulum (ER) (Mirazimi and Svens-
son, 1998). We analyzed potential N-linked glycosylation sites of
both RVA and RVC VP7s and found that there were three mainly
conserved N-linked glycosylation sites in each group. These sites
corresponded to aas 69, 146 and 238 in RVA, and 67, 152, and 225
in RVC (Fig. 6A, left and middle). Our results showed that RVs
could have different degrees of N-linked glycosylation. Around 34%
of RVA VP7s had a single glycosylation site at position 69% and 46%
had two sites at positions 69 and 238. A 3.3% population corre-
sponding to bovine/lamb RVA G10-types had two sites at positions
69 and 145. Interestingly, only 13.3% RVA VP7s had all three sites.
The remaining 3.4% were more divergent and had 1–4 sites mostly
at non-conserved positions. When we analyzed RVA VP7s with
three sites we found that most of these clustered in a single group
of human RVA G2-type VP7s (Fig. 6B). Most RVC VP7s had either
two sites (porcine groups) at positions 67 and 225, or three sites at
positions 67, 152 and 225 (human and porcine) or positions 67,
225 and 270 (bovine) (Fig. 6A, right). Interestingly, almost all
human and bovine RVC VP7s had three sites at the respective
conserved positions. In contrast, only a small population of porcine
VP7s (17%) had all three sites and a small percentage (o3%) had
2–3 sites at non-conserved positions.
Structural alignment of simian RVA VP7 and human RVC VP7
model showed that conserved N-linked glycosylation sites were
not aligned but in close proximity for positions 67/69 and 146/152
(Fig. 6C). On the contrary, the asparagine residues 225/238 were
located in distant positions on the opposite sites of the VP7 surface
indicating that this location was group speciﬁc (Fig. 6C). Of the
conserved sites only 67/69 are located on the N-terminus and not
on the protein surface. Glycosylation at position 69 for RVA (SA11
strain) has been conﬁrmed by biochemical assays (Mirazimi and-1b 7-2 L9 L4a L4b 
              Human RVC              Porcine RVC
Model Model
VC (green, top) and porcine-G6 RVC (cyan, bottom) VP7 model structures to simian
d magenta, respectively. L4b is shown in pink for porcine-G6 structure. (B) Surface
mAbs mapped on simian RVA (left), and simian RVA antigenic regions projected on
lso mapped on the surfaces. A color coding scheme is included at the bottom.
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Predicted epitope 1: NAAIGSPGPGK
Predicted epitope 2: SSSVNQLQ
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Fig. 5. Prediction of antigenic epitopes on RVC VP7 model surfaces by consensus
scoring. Surface residues are colored from red to blue according to the predicted
antigenicity (red, highest possibility; and blue, lowest possibility). (A) Human RVC
VP7 model and (B) Porcine-G6 RVC VP7 model. L9 and L4a insertions are shown in
red letters.
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structure a density is visible in close proximity to N69 that has
been modeled as N-acetyl-D-glucosamine molecules (NAG) (Set-
tembre et al., 2011). Studies related to the characterization of oli-
gosaccharide compositions of RVs has shown that oligosaccharides
of both simian (SA11) RVA and calf RVA likely exist as multiple
high-mannose forms (Both et al., 1983; Kouvelos et al., 1984).
Glycosylation of surface located conserved sites has not been
shown yet. However, it has been shown that a mutation at position
211 of RVA that creates a new N-linked glycosylation site prevents
the antibody recognition of region 7-1, indirectly showing that
surface N-linked glycosylation in RVA is possible (Mackow et al.,
1988).
RVC attachment protein VP4
RV VP4 proteins form spikes that project from the outer layer of
mature virions (Fig. 1A and B). VP4 mediates virion attachment to the
host epithelial cell receptors and plays a major role in cell penetra-
tion, hemagglutination and virulence (Crawford et al., 1994; Fiore
et al., 1991; Kirkwood et al., 1998; Ludert et al., 1996; Trask et al.,
2012). VP4 is susceptible to proteolysis and it is cleaved by trypsin
into two domains, VP8* and VP5* (Fig. 1A) (Clark et al., 1981;
Crawford et al., 2001; Espejo et al., 1981; Estes et al., 1981). Trypsin
cleavage of VP4 appears to increase RV infectivity, probably by
ordering otherwise ﬂexible uncleaved spikes (Settembre et al., 2011;Crawford et al., 2001). VP8* binds to host glycans in order to facilitate
host cell entry (Ciarlet and Estes, 1999; Fuentes-Panana et al., 1995;
Isa et al., 1997) and in integrin-dependent strains VP5* is thought to
target the integrin heterodimer ITGA2/ITGB1 for cell attachment
(Hewish et al., 2000; Zarate et al., 2000). In VP4, VP8* is the major
target for neutralizing antibodies.
A recent study that involved the phylogenetic analysis of 22
porcine VP4s revealed the presence of 6 clusters (Suzuki et al.,
2015). We extended that analysis to 70 human, porcine and bovine
RVC VP4 genes using an 78% nucleotide cut-off and identiﬁed 9P-
types some of which were divided into subgroups (as shown in
roman numerals) based on the length of their nucleotide sequence
in accordance to the system used by Suzuki et al. (2015) (Fig. 7A).
Similar to VP7, human and bovine VP4s clustered in single groups
while porcine VP4s showed higher variability (7P-types), which
was also observed for VP4 proteins (Fig. 7A and B). Our amino acid
sequence analysis also showed that compared to RVA VP4s, which
show a high degree of sequence variability (53–99.6% sequence
identity), RVC VP4s were more conserved (68–99.2% sequence
identity) (Table 3).
Human RVC VP4 proteins were longer in comparison to the
other RVC VP4s (744 aa). Bovine VP4s varied between 733 and 735
aa while porcine VP4s varied between 729 and 736 aa. Therefore,
we compared RVC VP4s and analyzed the positions of insertions
and deletions with respect to each other (Fig. 8A). Interestingly,
the majority of differences involve single or double aa insertions or
deletions (indels) mapped to VP8*, which plays an important role
in host receptor recognition and contains major antigenic epitopes
(Fig. 8B, left). The biggest structural difference between RVC VP8*
was caused by a 4 aa deletion between aa 209 and 213 which was
observed in some bovine and porcine strains (Fig. 8B, left). This
position partially involves β12 and the corresponding loop that
connects it to β13 in the human VP8* structure. Another difference
between human RVC VP8* and other RVC VP8* was an insertion
between aa 251 and 256 that corresponded to the foot region of
VP5* (Fig. 8B, right). However, due to trypsin cleavage of RVA VP5*
that region could only be seen in one of the VP4 molecules of the
heterotrimer, interacting with the rest of the foot region after
cleavage.
In human RVC (Bristol) VP4 we identiﬁed six potential trypsin
cleavage sites (K231, K244, K247, K248, K254 and K268) (Fig. 9A).
Of these, [KR]231 was conserved in all RVC VP4 proteins and K268
(K258 for RVA) was conserved in all RVC and RVAVP4s. It has been
shown that RVA VP4 is cleaved at K258 followed by the initial
cleavage of VP4 at positions 231, 241 and 247 (Crawford et al.,
2001; Gilbert and Greenberg, 1998).
Sequence alignment of human RVC (Bristol) VP4 model and
RVA (RRV) VP4 showed that RVA VP4 had a unique serine/threo-
nine/arginine rich insertion (STR-insertion, aa 571-620) located at
the “foot” of VP5* (Fig. 9A and B). This insertion is found in all RVA
VP4s with a high degree of conservation of serine and threonine
residues. However, to date no phosphorylation has been reported
for RVA VP4, and the role of the STR-insertion, if any, has yet to be
determined. Since in the capsid VP5* interacts both with the VP7
and VP6 layers it is not clear whether the absence of this loop
affects the backbone structures of these layers in the RVC capsid.
VP4 proteins are held in the capsid by multiple points of interac-
tions with VP6 (Settembre et al., 2011). In addition, production of
TLPs composed of RVA/RVC hybrid VP6 and VP7 layers suggest a
high similarity between the backbone structures of these layers in
both capsids (Kim et al., 2002). We hypothesized that the absence
of the STR-insertion probably would not induce large conforma-
tional changes in the backbone structures of RVC capsid proteins.
Analysis of RVA capsid structure revealed that the STR-insertion
extended towards the VP7 N-terminus and one of the VP6 loops
(Fig. 9C). However, the lack of high-resolution density at the foot
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Fig. 6. Potential N-linked glycosylation sites of VP7 proteins. (A) Graphical representation of predicted glycosylation sites for RVA (left) and RVC (middle) VP7 proteins.
Number of sequences used for the prediction (N) is shown on top left corner of the graphs. Distribution of most conserved N-linked glycosylation sites in human (red),
porcine (blue) and bovine (green) RVC VP7 groups are also shown (left). (B) Phylogenetic tree of RVA and human RVC VP7 proteins. Human RVA G2-type VP7 sequences with
3 N-linked glycosylation sites are shown in red and human RVC VP7s are shown in blue. Corresponding G-types based on Matthijnssens et al. (2012) are also shown.
(C) Mapping of potential conserved N-linked glycosylation sites on human RVC VP7 model. RVC conserved N-linked glycosylation sites are labeled and shown in magenta.
RVA conserved N-linked glycosylation site locations are projected on the RVC model and are shown in cyan.
Fig. 7. Phylogenetic analysis of RVC VP4. (A) Phylogenetic tree constructed using 70 RVC VP4 nucleotide sequences. (B) Phylogenetic tree constructed using 70 RVC VP4
protein sequences. Corresponding P-types (Suzuki et al., 2015) are shown in parenthesis. P-types that differ from the previously published P-types are indicated with
asterisks. Bootstrap values corresponding to the main nodes in both trees are shown.
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E. Eren et al. / Virology 487 (2016) 150–162158region of RVA prevented the analysis of protein–protein interac-
tions in detail so that we could not speculate about a direct
interaction of this region with either the VP7 N-terminus or VP6,
affecting the locking of VP7 layer in the RVA capsid. In RVC capsid
model, reduced VP4 foot at that region is not in close proximity to
either VP7 N-terminus or VP6 to form any direct hydrogen
bonding interactions.Table 3
Percent identity matrix of RVC VP4 proteinsa,b.
P1 P2 P3 P4
P1 85–100
P2 73–74 96–100
P3 77–81 72–74 90–100
P4 78 71–72 74–76 91–100
P5 75–76 69–70 74–76 75–76
P6 80–81 71–72 78–79 76–77
P7 76–78 70–71 75–77 73–76
P8 75–76 71 76–77 77
P9 75–76 68 73–75 73–74
a Percent identity matrix of RVC VP4 proteins forming different P-types were calcu
6 bits and a gap extension penalty of 1 bit.
b Number of independent sequences used for each P-type is as follows: P1: 4; P2: 2
Human-P2 TGPHTNTVIEWSNLW--- SVRLLTYNL AAFELWYNKT HDA
Porcine-P4 TGPHNNTVIEWSNLWVIA PVRLENY-V AAFELWYNNT VVL
Porcine-P5 SAENTGD-I LNNLT--- TKRLLSYVY AAFELWYENT VTV
Porcine-P7-I SAAHTNRVIEWSNLL--- TVKLLNYTL AAFELWY--V VAV
Porcine-P7-II SAAETNRVIEWSNLN--- TVKLLNYTL AAFELWY--V VAV
Porcine-P6-I SAAETNKVIEWKNLL--- TIKLLKYTL AACELWY--Q VRV
Porcine-P6-II SAAETNREIEWSNLN--- TVKLLNYTL AAFELWYNKQ VAV
Bovine-P3-I SAAHTNRVIEWSNLL--- TVKLLNYNL AAFELWYEKS VAV
Bovine-P3-II SAAETNRTIEWSNLN--- TVKLLNYNL AAFELWYEKS VAV
Porcine-P9   SAAETNRNIEWSNLN--- TVKLLNYYY AAFELWYS-- VAV
Porcine-P8   SAAETNRNIEWSNLN--- TVKLLNYYY AAFELWYS-- VAV
Porcine-P1-I SAAETNRIIEWSNLN--- TVKLLNYNL AAFELWYEKT VAV
Porcine-P1-II SAAETNRVIEWSNLN--- TVKLLNYK- AAFELWYKKT VAV
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Fig. 8. Sequence and structure comparisons of RVC VP4 proteins. (A) Sequence alignmen
and deletions (indels). For simplicity, regions without indels are shown as white boxes.
Accession numbers for sequences shown are: AAB00802, P1-1; BAQ15454, P1-2; YP
BAQ15456, P6-1; BAQ15464, P6-2; AJL35081, P7-1; AJL35080, P7-2; AJL35077, P8; AJL35
RVC VP4 with respect to other RVC VP4 proteins. Regions of insertions are shown in reRVC VP4 glycan binding sites
RVA VP8* proteins can be grouped into sialidase-sensitive and
sialidase-insensitive strains depending on their requirement to bind to
a host neuraminidase-sensitive sialic acid (SA) moiety to enter the cell
(Fiore et al., 1991; Ciarlet et al., 2001). Most RVA strains, including a
large majority of human RVAs, are sialidase-insensitive (Ciarlet andP5 P6 P7 P8 P9
84–100
74–82 90–100
72–77 82–85 83–100
76–78 78–79 75–77 100
73–74 74–76 76–79 82 100
lated using a Kimura-corrected pairwise alignment with a gap opening penalty of
5; P3: 7; P4: 8; P5: 12; P6: 7; P7: 4; P8: 1, P9: 2.
ILFW- SSRMRMEN DSFNWEFPGINI NMYTEYFA KTVDKMNDNSKLG DGPINVSSY
TLFW- GTRSDMDS TSFNHEFSNTNV SMYVEYDV TTVTAVN------ VSQEMRY--
VLFF- DGRVDINS NSFNWSFI---- SMYTEYYV KNMRLIK-----Q QGSINVD--
HNDSQ TPRIDMNS ETFNWEEGTI-- DIYIDSDI TTMQVIK------ NGQINTK--
HNDSQ TPRADMNS ETFNWEEGTIDI DIYIDYYI TMMQVIK------ NGQINTK--
NSDSQ NPRLNMTS DSFNFTLTTI-- NIVDSDPV TTFRVTK------ DTYMYDS--
HNDSN TPRADMNT ETFNWEETNINL DIYIDYYI TMMQVIK------ NGQINTK--
HNDS- TPRIDMNS ETFNWEE---SM DIYIDSDI TTMQVIK------ NGQINTK--
HNDS- TPRADMN- ETFNWEENNINI DIYIDYYI TMMQVIK------ NGQINTK--
HNDS- TPRADMNS ETFNWEEI---- DIYIDYY- TMMQVIK------ NGQINTK--
HNDS- TPRADMND ETFNWEEI---- DIYIDYY- TMMQVIK------ NGQINTK--
HNDS- TPRADMNS ETFNWEEVNINV DIYIDYYI TMMQVIK------ NGQINTK--
HNDS- TPRADMNA ETFNWEENDVNV DIYIDYYI TMMQVIK------ NGQINTK--
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t of representative VP4 proteins with different P-types showing sequence insertions
Numbering of amino acids on top is done according to human RVC VP4 sequence.
_392514, P2; BAO73942, P3-1; BAO73940, P3-2; BAQ15460, P4; BAQ15452, P5;
073, P9; and AIO05679, P10. (B) Structural mapping of amino acid indels on human
d and regions of deletions are shown in blue.
VP8*
VP5*
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Foot VP4 trimer foot
VP4
VP6
VP7
RVA
RVC
RVA Simian  1 MASLIYRQLLTNSYTVDLSDEIQEIGSTKTQNVTINPGPFAQTGYAPVNWGPGETNDSTTVEPVLDGPYQ 70RVC Human    1 MASSLYAQLISQNYYSLGNEILSDQQTNKVVSDYVDAGNYTYAQLPPTTWGSGSILKSAFSTPEITGPHT 70  
RVA Simian  71 PTTFNPP----VDYWMLLAPTAA----GVVVEGTNNTDRWLATILVEPNVTSETRSYTLFGTQEQITIAN 132 RVC Human   71 NTVIEWSNLINTNTWLLYQKPLNSVRLLKHGPDTYNSNLAAFELWYGKSGTTITSVYYNTINNQNKTHDA 140   
RVA Simian 133 ASQTQWKFIDVVKTTQNGSYSQYGPLQSTPKLYAVMKHNGKIYTYNGKTPNVTTRYYSTTN------YDS 196RVC Human  141 NSDCLILFWNEGSTQLEKQVVTFNWNVGGILIKPINSSRMRICMSGMENFNNDSFNWENWNHEFPRSNPG 210
RVA Simian 197 VNMTAFCDFYIIPREEESTCTEYINNGLPPIQNTRNIVPLALSARNIISHRAQANEDIVVSKTSLWKEMQ 266   RVC Human  211 ININMYTEYFLASS----DPYTYLKNLQQPTAKTVDMKMMKKMNDNSKLGDGPINVSNIISKDSLWQEVQ 276
RVA Simian 267 YNRDITIRFKFASSIVKSGGLGYKWSEISFKPANYQYTYTRDGEEVTAHTTCSVNGMNDFNFNGGSLPTD 336RVC Human  277 YVRDITLQCKILSEIVKGGGWGYDYTSVTFKTVNHTYSYTRAGENVNAHVTISFNNVKERAY-GGSLPTD 345   
RVA Simian 337 FVISRYEVIKENSYVYVDYWDDSQAFRNMVYVRSLAANLNSVI---CTGGDYSFALPVGQWPVMTGGAVS 403RVC Human  346 FKIGRFDILDTDSYVYIDYWDDSEIFKNMVYVRDVRADIGGFQYSYSSEMSYYFQIPVGSYPGLHSSRLQ 415
RVA Simian 404 LHSAGVTLSTQFTDFVSLNSLRFRFRLTVEEPSFSITRTRVSRLYGLPAANPNNGKEYYEVAGRFSLISL 473   RVC Human  416 LVYDRCLLSQQFTDYAALNSLRFVFRVVSTSGWFITTGDINTRRVASGTGFAYSDGHVANTVGTISFISL 485
RVA Simian 474 VPSNDDYQTPITNSVTVRQDLERQLGELREEFNALSQEIAMSQLIDLALLPLDMFSMFSGIKSTIDAAKS 543RVC Human  486 IPSNPNYQTPIASSSTVRMDLERKINDLRDDFNALASSVALSDILSLAMSPLTFSNLLESVPAITSSVKD 555
RVA Simian 544 MATSVMKKFKKSGLANSVSTLTDSLSDAASSISRGASIRSVGSSASAWTDVSTQITDVSSSVSSISTQTS 613RVC Human  556 VAASVMKKFRSTKMFKKAAKQNYREFV-----------------------IGDLLED------------- 589
RVA Simian 614 TISRRLRLKEMATQTEGMNFDDISAAVLKTKIDRSTQISPNTLPDIVTEASEKFIPNRAYRVINNDEVFE 683RVC Human  590 -------VTNVARNNNSLNYSDITSAMMVSTTNRLQITDVDTFSEIVSRSADNFISNRSYRMIENNTVHE 652
RVA Simian 684 AGTDGRFFAYRVETFDEIPFDVQKFADLVTDSPVISAIIDFKTLKNLNDNYGISRQQAFNLLRSDPRVLR 753RVC Human  653 IT-PTRRFSYDIKTLQQRNFDIDKFSKLASQSPVISAIVDFATIKAIRDTYGISDDIIYKLVASDAPTIL 721   
RVA Simian 754 EFINQDNPIIRNRIEQLIMQCRL 776    RVC Human  722 SFINQNNPLIRNRITNLINQCKL 744
Fig. 9. Sequence and structure comparisons of RVA and RVC VP4 proteins. (A) Sequence alignment of human RVC VP4 (YP_392514) with simian RVA (ACC94315). Simian RVA
sialic acid (SA) coordinating residues are shown in yellow. Trypsin cleavage sites are shown in green and integrin recognition peptide is shown in magenta. (B) Human RVC
VP4 monomer structure model (blue) aligned with simian RVA VP4 structure (gray) is shown on left. VP8* (head) and VP5* (body, stalk and foot) regions are indicated. The
50 aaSTR-insertion in the foot region of RVAVP4 is colored in red. Close-up view of the structural alignment of simian RVA VP4 trimer foot (gray) with RVC VP4 foot (blue) as
viewed from top (right). (C) Close-up view of the location of RVA STR-insertion in the capsid. VP7 is shown in green, VP6 is shown in yellow, RVA VP4 is shown in gray and
STR-insertion is shown in red. RVC VP4 (blue) is superimposed on RVA VP4 and the shorter connecting region of RVC VP4 is shown in dark blue.
E. Eren et al. / Virology 487 (2016) 150–162 159Estes, 1999). Sialidase-sensitive animal RVAs bind to glycans with a
terminal SA, whereas sialidase-insensitive human and animal strains
bind to glycans with either an internal SA, such as GM1 (Haselhorst
et al., 2009) or other non sialylated-glycans such as A-type histo-blood
group antigen (HBGA) (Hu et al., 2012). Although, the SA binding
properties of RVC VP8* proteins have not been extensively char-
acterized, one report suggested that a porcine RVC VP8* (strain AmC-
1) was sialidase-sensitive (Svensson, 1992). In order gain insight into
the glycan recognition by RVC VP4 proteins, we compared RVC
(Bristol) VP8* structure model to the sialidase-sensitive simian RVA
(RRV [PDB ID 1KQR]) structure that contains a 2-O-methyl-5-N-
acetyl-alpha-D-neuraminic acid (MNA) (Hu et al., 2012; Dormitzer
et al., 2002). Similar to RVA VP8* proteins, RVC VP8* model had the
beta-sandwich fold of galectins, a family of sugar binding proteins
(Lobsanov et al., 1993a, 1993b; Yang et al., 2008). In RVA sialidase-
sensitive strains, the key SA binding residues strongly conserved
(Dormitzer et al., 2002). Among these, the conservation of R101, Y189,
and S190, is absolute, while residues Y155 and Y189 can be mutated
to histidines (Fig. 10A, left) (Dormitzer et al., 2002). In Simian RVA
VP8* structure, SA binds in a shallow groove between its two ß-sheets
(Dormitzer et al., 2002). The groove has a large electropositive surface
formed mainly by R101 that coordinates the oxygen atoms of the
glycerol group of the SA (Fig. 10B, left). The SA acetamido amino group
points towards an electronegative surface formed by Y188 whichforms a hydrogen bond with the acetamido nitrogen, and S190
hydrogen bonds with the SA carboxylate group (Fig. 10B, left).
Sequence and structural alignment of the RVA VP8* substrate binding
site with RVC VP8* model showed that the amino acid composition of
substrate coordinating residues and surface charge distribution in
these structures were quite different (Fig. 10A and B) suggesting that
this site was probably not feasible for SA coordination in RVC. Sup-
porting this, docking of MNA to this site did not provide satisfactory
results. On the other hand, blind SA docking to RVC VP8* model using
AutoDock Vina (Trott and Olson, 2010) resulted in identiﬁcation of a
number of potential SA binding sites with calculated binding afﬁnit-
ies ranging from 4.7 kcal/mol to 5.4 kcal/mol (data not shown).
However, that did not suggest an absolute requirement of a terminal
SA for host cell entry.
It has been shown that RRV VP5* and human RVA (Wa strain)
contains the α2β1 ligand sequence D308GE310 and D308 and G309
are necessary for the binding of VP5* to I domain of the α2 integrin
subunit (Graham et al., 2006). We compared RVC VP5* and RVA VP5*
sequences to analyze if RVC could also recognize α2β1. In RVC VP5*
proteins the conserved DGE were replaced by conserved “[AS] GE”
(Fig. 9A). Site-directed mutagenesis studies has shown that a double
mutant (D308A/G309A) lost its ability to bind to α2β1 (Graham et al.,
2006). Therefore, it is unlikely that RVC VP5* will recognize α2β1 by
its [AS]GE sequence. However, RVC VP5* might contain other domains
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Fig. 10. Comparison of carbohydrate binding sites of RVA and RVC VP4 proteins. (A) Sialic acid (SA) binding site of simian RVA VP8* (PDB ID 1KQR) (left) and structural
alignment of simian RVA VP4 SA binding site (gray) with human RVC VP4 model (blue, right). RVA residues coordinating SA are shown at the top and corresponding RVC
residues are shown at the bottom. (B) Electrostatic surface potentials for simian RVA VP8* (left), and human RVC VP8* model (right). SA binding site is indicated with a box
on both surfaces.
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RVA CRW-8 VP5* (Graham et al., 2006).Discussion
Virus capsid structures play an important role in vaccine
development, drug targeting and improvement of immuno-
diagnostic tools. Although the most widely used methods for
determination of capsid structures are cryo-EM and X-ray crys-
tallography, the availability of new bioinformatics tools enables
the generation of capsid models for virus strains that are hard to
crystallize or cannot be obtained in high quantities necessary for
these applications. One such example is the human rhinovirus C
(C15) capsid model developed by Basta et al. (2014) which enabled
the authors to determine the underlying reasons for the antiviral
drug resistance of this strain.
To date at least 8 different RV species have been identiﬁed.
However, structural information is only available for RVA, partly
due to difﬁculties in the adaptation of other strains to growth in
cell culture. To this end, we generated a RVC capsid model by
homology modeling and compared RVA capsid and RVC capsid
model in order to understand the structural features that might
underlie the differences between the pathogenicity of these two
RV groups. This comparison enabled us to deﬁne new group/host
speciﬁc (L4) or generally conserved (L9) surface exposed loops at
the RVC VP7 layer that potentially form major antigenic sites
which are absent from the RVA capsid surface. L4 is found only in a
speciﬁc group (G6) of porcine-RVCs and probably does not play an
important role in VP7 physiology. On the other hand, L9 is present
in all RVCs regardless of host speciﬁcity and its sequence has a
high degree of conservation. Although, at this point it is not clear
whether L9 forms a novel domain that plays a role in RVCpathogenicity i.e. host cell/compartment entry, it can be used in
seroepidemiological studies for RVC identiﬁcation. In addition, its
surface exposed location in VP7 makes it a good target for genetic
engineering of RVC or RVA outer capsids in vitro.
Glycoproteins ﬁgure prominently in a number of viruses and
mutations at the surface exposed glycosylation sites often interfere
with viral entry, infectivity, tissue speciﬁcity, or host range,
implying roles in cell recognition, membrane fusion and cell entry
(Delos et al., 2002; Shirato et al., 2004). Our analysis showed that
both RVA and RVC VP7 proteins have potential N-linked glycosy-
lation sites at conserved locations at the N-terminus or on the
surface. However, both strains could adopt different levels of gly-
cosylation (0–4 sites for RVA and 2–3 sites for RVC) and in general
RVC VP7s contained a higher number of potential N-linked gly-
cosylation sites in comparison to RVA VP7s (1–2 sites for RVA and
2–3 sites for RVC). RVC VP7 model has an increased surface area
with highly probable antigenic properties suggesting that there
might be a correlation between the degree of accessible antigenic
regions and the number of N-linked glycosylation sites. Indeed, as
has been suggested for HIV, glycosylation sites provide variability
that allows the virus to escape immune detection of nearby con-
served amino acids at the receptor-binding site and modulate
antigenicity (Botarelli et al., 1991; Hause et al., 2012). Further
supporting this, in RV it has been possible to select monoclonal
neutralization escape mutants that have new glycosylation sites in
a deﬁned epitope (Lazdins et al., 1995).
RVA-RVC hybrid TLPs composed of VP2, VP6 and VP7 have been
produced indicating that the reassortment of these viruses is possible
at the capsid level. However, no research has been conducted to test
the incorporation of VP4, which shows the highest degree of varia-
bility among capsid proteins, in these hybrid TLPs. Our homology
model and sequence alignment showed that RVA and RVC VP4 differ
at the foot region, which protrudes towards the intermediate capsid
E. Eren et al. / Virology 487 (2016) 150–162 161layer. Even though our model and hybrid TLPs suggest a similar
backbone arrangement at the VP2, VP6, and VP7 layer for both RVA
and RVC capsids, further structural and biochemical studies are
required to determine whether VP4 presents a structural barrier for
the reassortment of these viruses.
Comparison of RVA and RVC VP8* molecules showed no simi-
larity between the two structures at the SA binding site of RVA.
One possibility is the recognition of a different receptor by this site
and another is the presence of alternative binding sites on the RVC
VP8* surface. Previous biochemical studies showed a terminal SA
residue dependence of a porcine RVC strain for host cell entry
(Svensson, 1992). We identiﬁed potential binding pockets on the
RVC VP8* model surface that might interact with SA. However,
these sites have yet to be veriﬁed either by structural or site-
directed mutagenesis experiments. Also, it is possible that SA-
independent RVC strains exist as in the case of RVA. Interestingly,
RVCs lack the conserved sequences at the VP5* integrin binding
sites underlying differences in host receptor recognition by RVA
and RVC strains. We found insertion/deletion mutations among
different RVC groups in the VP8*, where most antigenic regions of
the RV VP4 are located. It is a common mechanism to generate and
maintain mutations that allow viruses to escape from antibody
neutralization, so further comparative analysis of these regions
could lead to a better understanding of how RVs evolve under
selective immune pressure.
In conclusion, our modeled RVC capsid provided a useful tool to
study the biology of this virus group from a structural perspective
and enabled us to identify some structural differences that prob-
ably underlie the differences between the antigenicity and host
cell receptor recognition by these two strains. We believe our work
provides a framework for comparative studies with other
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